Introduction to Disability Assessment

In two patients with status migrainosus, migraine-related disability 3 months prior and after treatment using MIDAS (Migraine Disability Assessment) questionnaire was recorded.

The effect of pain-related emotion on migraine-related disability assessed with the Headache Impact Test-6 (HIT-6) and the Migraine Disability Assessment (MIDAS).

The manifestations of post-RCVS headache and headache-related disability measured by Migraine Disability Assessment (MIDAS) scores were recorded.

Background Migraine Disability Assessment Scale (MIDAS) is a useful tool to measure headache-related disability.

visual analog scale (VAS) and migraine disability assessment (MIDAS) questionnaires were used by a neurologist for assessing migraine disability and pain severity, respectively.

Each patient also completed the following questionnaires: (1) Migraine Disability Assessment Scale (MIDAS); (2) headache severity with VAS (Visual Analog Scale); (3) Allodynia Symptom Checklist (ASC-12); (4) Beck Depression Inventory (BDI); (5) World Health Organization Quality of Life Questionnaire Short Form-12 (WHOQL-SF12); (6) Activities Specific Balance Confidence Scale (ABC).

QoL was assessed using Health-Related Quality of Life in Stroke Patients (HRQOLISP-40) and disability was measured by using the World Health Organization Disability Assessment Schedule 2.

At predefined times, the various outcomes (pain intensity, health-related quality of life, pain duration, autonomic regulation, and heart rate variability) as well as the participants’ acceptance of the complex treatment will be evaluated with valid assessment instruments (Migraine Disability Assessment, PHQ-D, GAD-7, and SF-12) and a headache diary.

The psychometric analyses included reliability by internal consistency (Cronbach’s alpha) and test/retest stability (intraclass correlation coefficient, ICC); construct validity was investigated by matching (a priori hypotheses) the CFPDI-I with the Italian Neck Disability Index (NDI-I), a pain intensity numerical rating scale (NRS), the Italian Pain Catastrophising Scale (PCS-I), the Italian Tampa Scale of Kinesiophobia (TSK-I), and the Italian Migraine Disability Assessment Score Questionnaire (MIDAS) (Pearson’s correlation).

METHODS Data were collected before operation, in the PACU, 72 h after surgery and 3 months after surgery, and included numerical rating scale (NRS) scores for pain, and modified Brief Pain Inventory-Short Form, Kessler Psychological Distress Scale, World Health Organization Disability Assessment Schedule, and Pain Catastrophizing Scale scores.

Sex, income, cutaneous allodynia, and medication overuse were modeled as binary variables; age, body mass index, headache-related disability (Migraine Disability Assessment [MIDAS]), and Migraine Symptom Severity Scale as continuous variables.

Detailed systemic and neurological examinations, and blood pressure, weight, height, and body mass index measurements, clinical and demographical data, the visual analog scale, allodynia symptom checklist, and the Migraine Disability Assessment Scale (MIDAS) scores were recorded.

The Hamilton depression and anxiety inventories, visual analogue scale for assessing the severity of pain, and the Migraine disability assessment (MIDAS) test were used before and after CBT.

The age of disease onset, headache duration and frequency, presence of aura and type of aura, clinical properties and location of headache, pain severity, trigger factors, presence of family history, visual analogue scale (VAS) and Allodynia Symptom Checklist (ASC) scores, presence of allodynia, and Migraine Disability Assessment (MIDAS) scores were recorded and the 2 groups were compared statistically.

Construct validity was investigated using Roland Morris Disability Questionnaire, World Health Organisation Disability Assessment Schedule, Fear Avoidance Beliefs Questionnaire and eleven-point box scale of pain intensity; and exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) using randomly selected 200 adults with CLBP in rural Nigeria.

Construct validity testing involving correlations between Igbo-HADS and Roland Morris Disability Questionnaire measuring self-reported back pain-specific disability, World Health Organisation Disability Assessment Schedule assessing generic self-reported disability, Fear Avoidance Beliefs Questionnaire measuring fear avoidance beliefs, and eleven-point box scale assessing pain intensity, and exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) among a random sample of 200 adults with CLBP in rural Nigerian communities were conducted.

Main outcome measures Caregiver burden (self-reported, Burden Scale for Family Caregivers), pragmatic communication skills of people without natural speech (proxy report, self-developed), health-related quality of life of people without natural speech (proxy report, DISABKIDS Chronic Generic Measure - DCGM-12) and functioning of people without natural speech (proxy report, WHO Disability Assessment Schedule 2.

The following instruments were administered: (a) Positive and Negative Syndrome Scale (PANSS), (b)World Health Organization Disability Assessment Schedule 2.

Level of functioning was also assessed by self-report and clinician-rated World Health Organization Disability Assessment Schedule 2.

Main Outcome Measures The Migraine Disability Assessment (MIDAS) questionnaire was used before and 6 months after surgery for the assessment of headache.

Disability evaluated using change in patient reported Migraine Disability Assessment (MIDAS) scores from baseline were considered for the final analysis.

Cognitive functioning (Montreal Cognitive Assessment–blind), anxiety and depression (Hospital Anxiety and Depression Scale), post-traumatic stress (Impact of Event Scale-Revised) symptoms, disability (WHO Disability Assessment Schedule 2.

Health status was measured by the WHO Disability Assessment Scale (WHO-DAS 2.

Measures included change in physical activity since physically and socially isolating (Likert scale) and disability (Barthel Index and Lawton–Brody IADL scale) or difficulty (World Health Organisation Disability Assessment Schedule-2.

Efficacy will be assessed on the Anxiety, Depression, and Mood Scale; Kessler-10; and the World Health Organisation Disability Assessment Schedule 2.

In many countries inability to work fulltime is recognized as an important concept in work disability assessments.

Little is known about trajectories of self-perceived cognitive functioning in cancer survivors in the period after work disability assessment.

The World Health Disability Assessment Scale (WHODAS-2.

0-BO for older Brazilians (World Health Disability Assessment Schedule – Brazilian version for older people) and its distribution according to sex, age, health, subjective health perception, performance in a mobility test and presence of chronic diseases and depression.

We evaluated age, scores on the Brief Pain Inventory (BPI), Pain Catastrophizing Scale, Pain Disability Assessment Scale (PDAS), Hospital Anxiety and Depression Scale, Pain Self-Efficacy Questionnaire (PSEQ), EuroQol Five Dimensions Questionnaire, and Athens Insomnia Scale (AIS).

Demographic and clinical information were collected, including the Pain Disability Assessment Scale (PDAS), the Pain Self-Efficacy Questionnaire (PSEQ), the Hospital Depression and Anxiety Scale, and the Numeric Rating Scale (NRS) to assess pain intensity.

To evaluate the motor function of infants we used Pediatric Motor Activity Log (PMAL-R) and Manual Function Evaluation (AMIGO), and to assess the caregiver's perception of the participation of the infant in daily tasks, we used the Pediatric Disability Assessment Inventory (PEDI).

A child identification questionnaire was applied as an inclusion criterion and the selected participants were assessed through the Pediatric Disability Assessment Inventory (PEDI) and the sociodemographic interview (ABEP).

Randomized and observational studies with pain relief score and/or functional disability assessment and at least a 2-week follow-up were included.

Numeric rating scale (NRS), Oswestry Disability Index (ODI) and Effective rate will be measured in pain and functional disability assessment, respectively, as the primary outcome.

The following instruments were administered: (a) Positive and Negative Syndrome Scale (PANSS), (b)World Health Organization Disability Assessment Schedule 2.

Cognitive functioning (Montreal Cognitive Assessment–blind), anxiety and depression (Hospital Anxiety and Depression Scale), post-traumatic stress (Impact of Event Scale-Revised) symptoms, disability (WHO Disability Assessment Schedule 2.

1 (MSQ), Migraine Disability Assessment Scale (MIDAS), and Work Productivity and Activity Impairment (WPAI) questionnaire.

Health status was measured by the WHO Disability Assessment Scale (WHO-DAS 2.

The Migraine Disability Assessment score was higher for participants with migraine [median and interquartile range, 3.

Specified questions about the sociodemographic characteristics, migraine attacks and medications, and the items of Migraine Disability Assessment score (MIDAS), were included in the next parts of the survey.

Patients were subjected to Hamilton depression and anxiety rating scales along with, Migraine Disability Assessment Questionnaire (MIDAS) for assessing disability.

METHODS Participants responded to the questionnaires Migraine Disability Assessment questionnaire, 12-item Allodynia Symptom Checklist and Neck Disability Index.

Data here reported shows that erenumab and galcanezumab reduced mean headache days, acute migraine specific medication days, Headache Impact Test score, Migraine Disability Assessment Test score and Visual Analogue Scale score after 3 and 6 doses in real-world patients diagnosed with difficult to treat chronic or episodic migraine (p<0.

The functional head impulse test was applied to both groups, and the migraine disability assessment test was applied to migraine patients.

0 disability assessment tool, a generic assessment instrument for health and disability.

Outcome measures included migraine disability (using Migraine Disability Assessment tool [MIDAS]), headache self-efficacy (using Headache Management Self-Efficacy Scale [HMSE]), acute medication use, and migraine frequency.

Galcanezumab (120-mg and 240-mg) significantly improved the Migraine-Specific Quality of Life Questionnaire role function-restrictive domain score as well as the Migraine Disability Assessment total score versus placebo for patients with LFEM or HFEM.

Moderate-to-severe headache-related disability (Migraine Disability Assessment total score ≥ 11) was reported by significantly fewer patients with EM than with CM (21.

To evaluate the motor function of infants we used Pediatric Motor Activity Log (PMAL-R) and Manual Function Evaluation (AMIGO), and to assess the caregiver's perception of the participation of the infant in daily tasks, we used the Pediatric Disability Assessment Inventory (PEDI).

A child identification questionnaire was applied as an inclusion criterion and the selected participants were assessed through the Pediatric Disability Assessment Inventory (PEDI) and the sociodemographic interview (ABEP).

Factors affecting access included the accessibility of the application process, complexity of disability assessment procedures, awareness of programmes and their eligibility requirements and the perceived utility of benefits.

Factors affecting access included the accessibility of the application process, disability assessment procedures, awareness and the perceived utility of programmes, and attitudes on disability and social protection.